These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8450427)

  • 1. Influence of pH on release of phenytoin sodium from slow-release dosage forms.
    Serajuddin AT; Jarowski CI
    J Pharm Sci; 1993 Mar; 82(3):306-10. PubMed ID: 8450427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
    Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
    J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microenvironmental pH modulation in solid dosage forms.
    Badawy SI; Hussain MA
    J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Dissolution Media and Presence of Alcohol on the In Vitro Performance of Pharmaceutical Products Containing an Insoluble Drug.
    Friuli V; Bruni G; Musitelli G; Conte U; Maggi L
    J Pharm Sci; 2018 Jan; 107(1):507-511. PubMed ID: 28624418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compatibility and pH variability of four injectable phenytoin sodium products.
    Markowsky SJ; Kohls PR; Ehresman D; Leppik I
    Am J Hosp Pharm; 1991 Mar; 48(3):510-4. PubMed ID: 2028998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle.
    Niwa T; Shimabara H; Kondo M; Danjo K
    Int J Pharm; 2009 Dec; 382(1-2):88-97. PubMed ID: 19686828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semisolid matrix filled capsules: an approach to improve dissolution stability of phenytoin sodium formulation.
    El Massik MA; Abdallah OY; Galal S; Daabis NA
    Drug Dev Ind Pharm; 2003 May; 29(5):531-43. PubMed ID: 12779283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
    Chrzanowski FA; Ahmad K
    Drug Dev Ind Pharm; 2017 Mar; 43(3):421-431. PubMed ID: 27808569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro release testing of matrices based on starch-methyl methacrylate copolymers: effect of tablet crushing force, dissolution medium pH and stirring rate.
    Ferrero C; Jiménez-Castellanos MR
    Int J Pharm; 2014 Jan; 461(1-2):270-9. PubMed ID: 24333902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modular solid dosage form design - Application to pH-independent release of a weak-base API.
    Cano-Vega MA; Deng M; Pinal R
    Int J Pharm; 2021 May; 601():120518. PubMed ID: 33775729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability study of a freeze-dried sodium phenytoin-milk formulation.
    Macheras P; Ismailos G; Reppas C
    Biopharm Drug Dispos; 1991 Dec; 12(9):687-95. PubMed ID: 1790313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
    Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
    Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
    Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of phenytoin sodium capsules available in Thailand. Part I: In vitro study.
    Suthisisang C; Payakachat N
    J Med Assoc Thai; 1998 Jan; 81(1):58-63. PubMed ID: 9470323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
    Riis T; Bauer-Brandl A; Wagner T; Kranz H
    Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules.
    Wilder BJ; Leppik I; Hietpas TJ; Cloyd JC; Randinitis EJ; Cook J
    Neurology; 2001 Aug; 57(4):582-9. PubMed ID: 11524464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium.
    Rahman Z; Dharani S; Barakh Ali SF; Afrooz H; Reddy IK; Khan MA
    Int J Pharm; 2018 Oct; 550(1-2):290-299. PubMed ID: 30031866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.